Literature DB >> 15470339

Substantially elevated levels of atorvastatin and metabolites in cyclosporine-treated renal transplant recipients.

M Hermann, A Asberg, H Christensen, H Holdaas, A Hartmann, J L E Reubsaet.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2004        PMID： 15470339     DOI： 10.1016/j.clpt.2004.07.008

Source DB:  PubMed          Journal:  Clin Pharmacol Ther        ISSN： 0009-9236            Impact factor:   6.875


× No keyword cloud information.
  17 in total

1.  Diabetes mellitus reduces the clearance of atorvastatin lactone: results of a population pharmacokinetic analysis in renal transplant recipients and in vitro studies using human liver microsomes.

Authors:  Miroslav Dostalek; Wai-Johnn Sam; Komal R Paryani; Joyce S Macwan; Reginald Y Gohh; Fatemeh Akhlaghi
Journal:  Clin Pharmacokinet       Date:  2012-09-01       Impact factor: 6.447

2.  Atorvastatin does not affect the pharmacokinetics of cyclosporine in renal transplant recipients.

Authors:  Monica Hermann; Anders Asberg; Hege Christensen; Jan Leo Egge Reubsaet; Hallvard Holdaas; Anders Hartmann
Journal:  Eur J Clin Pharmacol       Date:  2005-02-12       Impact factor: 2.953

3.  Biomarker assessment of the immunomodulator effect of atorvastatin in stable renal transplant recipients and hypercholesterolemic patients.

Authors:  David Guillén; Federico Cofán; Emilio Ros; Olga Millán; Montse Cofán; Mercè Brunet
Journal:  Mol Diagn Ther       Date:  2010-12-01       Impact factor: 4.074

Review 4.  Influence of drug transporter polymorphisms on pravastatin pharmacokinetics in humans.

Authors:  Kari T Kivistö; Mikko Niemi
Journal:  Pharm Res       Date:  2006-12-20       Impact factor: 4.200

5.  Successful strategy to improve the specificity of electronic statin-drug interaction alerts.

Authors:  Hanna Marita Seidling; Caroline Henrike Storch; Thilo Bertsche; Christian Senger; Jens Kaltschmidt; Ingeborg Walter-Sack; Walter Emil Haefeli
Journal:  Eur J Clin Pharmacol       Date:  2009-07-30       Impact factor: 2.953

6.  Assessment of Drug-Drug Interaction Potential Between Atorvastatin and LCZ696, A Novel Angiotensin Receptor Neprilysin Inhibitor, in Healthy Chinese Male Subjects.

Authors:  Surya Ayalasomayajula; Wei Pan; Yi Han; Fan Yang; Thomas Langenickel; Parasar Pal; Wei Zhou; Yaozong Yuan; Iris Rajman; Gangadhar Sunkara
Journal:  Eur J Drug Metab Pharmacokinet       Date:  2017-04       Impact factor: 2.441

7.  Statin post-treatment provides protection against simulated ischemia in bovine pulmonary arterial endothelial cells.

Authors:  Xing Wu; Daowei Lin; Guofu Li; Zhiyi Zuo
Journal:  Eur J Pharmacol       Date:  2010-03-31       Impact factor: 4.432

Review 8.  Pediatric Statin Administration: Navigating a Frontier with Limited Data.

Authors:  Jonathan Wagner; Susan M Abdel-Rahman
Journal:  J Pediatr Pharmacol Ther       Date:  2016 Sep-Oct

Review 9.  Impact of OATP transporters on pharmacokinetics.

Authors:  A Kalliokoski; M Niemi
Journal:  Br J Pharmacol       Date:  2009-09-25       Impact factor: 8.739

10.  Association of the TNF-{alpha}-C-857T polymorphism with resistance to the cholesterol-lowering effect of HMG-CoA reductase inhibitors in type 2 diabetic subjects.

Authors:  Toru Takahashi; Kazuma Takahashi; Mitsuhiro Yamashina; Chihaya Maesawa; Takashi Kajiwara; Haruhito Taneichi; Noriko Takebe; Yoshihito Kaneko; Tomoyuki Masuda; Jo Satoh
Journal:  Diabetes Care       Date:  2009-12-10       Impact factor: 19.112
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.